It is totally the case.....the twice daily oxycodone that Purdue put out would be a good bet....it is now off Patent and Purdue made 3 billion off this product.....now it is off patent....attach Elite's ART to it......off of a less costly BE trial....and you get the same market cap from an abuse generic twice daily oxy......as you would from an AR Eli 216......with less cost......the FDA just threw ELTP a huge bone!!!!